Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study

Simple item page
dc.contributor.authorHiwase, D.
dc.contributor.authorTan, P.
dc.contributor.authorD'Rozario, J.
dc.contributor.authorTaper, J.
dc.contributor.authorPowell, A.
dc.contributor.authorIrving, I.
dc.contributor.authorWright, M.
dc.contributor.authorBranford, S.
dc.contributor.authorYeung, D.T.
dc.contributor.authorAnderson, L.
dc.contributor.authorGervasio, O.
dc.contributor.authorLevetan, C.
dc.contributor.authorRoberts, W.
dc.contributor.authorSolterbeck, A.
dc.contributor.authorTraficante, R.
dc.contributor.authorHughes, T.
dc.date.issued2018
dc.descriptionData source: Supplementary data, https://doi.org/10.1016/j.leukres.2018.02.013
dc.description.abstractBackground: Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic phase chronic myeloid leukemia (CML-CP) experience intolerable adverse events. Management strategies include dose adjustments, interrupting or discontinuing therapy, or switching to an alternative TKI. Methods: This multicenter, single-arm, Phase IIIb study included CML-CP patients intolerant of, but responsive to, first-line treatment with imatinib or dasatinib. All patients were switched to nilotinib 300 mg bid for up to 24 months. The primary endpoint was achievement of MR4.5 (BCR-ABL transcript level of ≤0.0032% on the International Scale) by 24 months. Results: Twenty patients were enrolled in the study (16 imatinib-intolerant, 4 dasatinib-intolerant); which was halted early because of low recruitment. After the switch to nilotinib 300 mg bid, MR4.5 at any time point up to month 24 was achieved in 10 of 20 patients (50%) in the full analysis set. Of the non-hematological adverse events associated with intolerance to prior imatinib or dasatinib, 74% resolved within 12 weeks of switching to nilotinib 300 mg bid. Conclusion: Nilotinib 300 mg bid shows minimal cross intolerance in patients with CML-CP who have prior toxicities to other TKIs and can lead to deep molecular responses.
dc.description.statementofresponsibilityDevendra Hiwase, Peter Tan, James D’Rozario, John Taper, Anthony Powell, Ian Irving, Matthew Wright, Susan Branford, David T. Yeung, Luke Anderson, Othon Gervasio, Carly Levetan, Will Roberts, Ann Solterbeck, Robert Traficante, Timothy Hughes
dc.identifier.citationLeukemia Research, 2018; 67:109-115
dc.identifier.doi10.1016/j.leukres.2018.02.013
dc.identifier.issn0145-2126
dc.identifier.issn1873-5835
dc.identifier.orcidHiwase, D. [0000-0002-6666-3056]
dc.identifier.orcidBranford, S. [0000-0002-1964-3626] [0000-0002-5095-7981]
dc.identifier.orcidYeung, D.T. [0000-0002-7558-9927]
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.urihttp://hdl.handle.net/2440/121244
dc.language.isoen
dc.publisherElsevier
dc.rights© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
dc.source.urihttps://doi.org/10.1016/j.leukres.2018.02.013
dc.subjectNilotinib; tyrosine kinase inhibitor; chronic myeloid leukemia
dc.titleEfficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_121244.pdf
Size:
423.54 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications